News and breakthroughs in tissue analysis, biomarkers, and pathology technology.
October 31, 2018 – Flagship Biosciences is honored to be named by Industry Era Magazine as one of the 10 Best Technology Solution Providers of
Predicine and Flagship Biosciences are excited to announce a strategic venture to provide complimentary and comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) space.
Frost & Sullivan News Release: Flagship Biosciences Recognized by Frost & Sullivan for Its Industry-leading AI-powered cTA® Platform for Predictive Diagnostics Santa Clara, CA, September
Flagship’s Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine
Westminster, CO, September 6, 2018 – Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be
Westminster, CO, July 10, 2018 – Flagship Biosciences has closed a series A round of funding to advance the growth of its computational tissue image
Flagship publishes article on using IHC and digital imaging to improve patient selection for PD-L1 therapy
First NSCLC study using cTA to report IHC data in immuno-oncology Westminster, CO, June 7, 2018 – Flagship is proud to co-author the research paper,